Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-04-18 4:15 pm Sale | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Athyrium Opportunities III Acquisition 2 LP | 0 0% | -44,286,346 (Position Closed) | View |
| 2023-02-13 10:24 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Stonepine Capital Management LLC | 31,666,195 9.9% | 1,317,320 (+4.34%) | View |
| 2023-02-10 4:00 pm Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Rubric Capital Management LP | 18,000,000 5.61% | 277,660 (+1.57%) | View |
| 2023-02-10 09:48 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 31,667,760 9.9% | 4,379,262 (+16.05%) | View |
| 2022-02-14 10:34 am Sale | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | UBS OCONNOR LLC | 9,950,000 3.11% | -3,263,340 (-24.70%) | View |
| 2022-02-14 08:59 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Rubric Capital Management LP | 17,722,340 5.59% | 17,722,340 (New Position) | View |
| 2022-02-11 4:24 pm Unchanged | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | EdgePoint Investment Group Inc. | 0 0% | 0 (Unchanged) | View |
| 2022-02-11 2:27 pm Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Stonepine Capital Management LLC | 30,348,875 9.5% | 19,266,460 (+173.85%) | View |
| 2022-02-11 08:18 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 27,288,498 8.53% | 2,589,665 (+10.48%) | View |
| 2021-05-05 5:07 pm Unchanged | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | EdgePoint Investment Group Inc. | 0 0% | 0 (Unchanged) | View |
| 2021-02-16 10:32 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | UBS OCONNOR LLC | 13,213,340 7.3% | 13,213,340 (New Position) | View |
| 2021-02-12 4:37 pm Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Stonepine Capital Management LLC | 11,082,415 6.2% | 11,082,415 (New Position) | View |
| 2021-02-12 08:01 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | Athyrium Opportunities III Acquisition 2 LP | 44,286,346 24.8% | 44,286,346 (New Position) | View |
| 2021-02-05 08:18 am Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | HIGHBRIDGE CAPITAL MANAGEMENT LLC | 24,698,833 9.99% | 24,698,833 (New Position) | View |
| 2020-12-22 4:21 pm Purchase | 13G | AMRYT PHARMA PLC SPONSORED ADR AMYT | STONEPINE CAPITAL L.P. | 11,050,350 6.2% | 11,050,350 (New Position) | View |